182 related articles for article (PubMed ID: 29948442)
21. Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis.
Zhou T; Lin S; Yang S; Lin W
Drug Des Devel Ther; 2019; 13():857-869. PubMed ID: 30880918
[TBL] [Abstract][Full Text] [Related]
22. Multitarget Therapy for Maintenance Treatment of Lupus Nephritis.
Zhang H; Liu Z; Zhou M; Liu Z; Chen J; Xing C; Lin H; Ni Z; Fu P; Liu F; Chen N; He Y; Liu J; Zeng C; Liu Z
J Am Soc Nephrol; 2017 Dec; 28(12):3671-3678. PubMed ID: 28760751
[TBL] [Abstract][Full Text] [Related]
23. Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis.
Tanaka H; Tsugawa K; Suzuki K; Nakahata T; Ito E
Pediatr Nephrol; 2006 Jul; 21(7):962-6. PubMed ID: 16773408
[TBL] [Abstract][Full Text] [Related]
24. Study of the efficacy of mizoribine in lupus nephritis in Chinese patients.
Zhang M; Xing CY; Liu J
Rheumatol Int; 2013 Nov; 33(11):2737-42. PubMed ID: 23797779
[TBL] [Abstract][Full Text] [Related]
25. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
Jesus D; Rodrigues M; da Silva JAP; Inês L
Lupus; 2018 Jul; 27(8):1358-1362. PubMed ID: 29448882
[TBL] [Abstract][Full Text] [Related]
26. A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis.
F L; Y T; X P; L W; H W; Z S; H Z; Z H;
Lupus; 2008 Jul; 17(7):622-9. PubMed ID: 18625634
[TBL] [Abstract][Full Text] [Related]
27. Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study.
Fei Y; Wu Q; Zhang W; Chen H; Hou Y; Xu D; Li M; Zhang X; Zhao Y; Zeng X; Zhang F
Clin Exp Rheumatol; 2013; 31(1):62-8. PubMed ID: 22935463
[TBL] [Abstract][Full Text] [Related]
28. Multitarget therapy versus intravenous cyclophosphamide in the induction treatment of lupus nephritis: a metaanalysis of randomized controlled trials.
Deng J; Luo L; Zhu L; Xie H; xie H
Turk J Med Sci; 2018 Oct; 48(5):901-910. PubMed ID: 30384552
[TBL] [Abstract][Full Text] [Related]
29. Tacrolimus is effective for lupus nephritis patients with persistent proteinuria.
Uchino A; Tsukamoto H; Nakashima H; Yoshizawa S; Furugo I; Mitoma H; Oryoji K; Shimoda T; Niiro H; Tada Y; Yano T; Nonaka T; Oishi R; Akashi K; Horiuchi T
Clin Exp Rheumatol; 2010; 28(1):6-12. PubMed ID: 20346231
[TBL] [Abstract][Full Text] [Related]
30. Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis.
Yumura W; Suganuma S; Uchida K; Moriyama T; Otsubo S; Takei T; Naito M; Koike M; Nitta K; Nihei H
Clin Nephrol; 2005 Jul; 64(1):28-34. PubMed ID: 16047642
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis.
Lanata CM; Mahmood T; Fine DM; Petri M
Lupus; 2010 Jul; 19(8):935-40. PubMed ID: 20388722
[TBL] [Abstract][Full Text] [Related]
32. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study.
Mok CC; Tong KH; To CH; Siu YP; Au TC
Kidney Int; 2005 Aug; 68(2):813-7. PubMed ID: 16014060
[TBL] [Abstract][Full Text] [Related]
33. Implication of the peak serum level of mizoribine for control of the serum anti-dsDNA antibody titer in patients with lupus nephritis.
Tanaka H; Tsugawa K; Nakahata T; Kudo M; Suzuki K; Ito E
Clin Nephrol; 2005 Jun; 63(6):417-22. PubMed ID: 15960142
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of class V+IV lupus nephritis with multitarget therapy.
Bao H; Liu ZH; Xie HL; Hu WX; Zhang HT; Li LS
J Am Soc Nephrol; 2008 Oct; 19(10):2001-10. PubMed ID: 18596121
[TBL] [Abstract][Full Text] [Related]
35. Tacrolimus use in lupus nephritis: A systematic review and meta-analysis.
Hannah J; Casian A; D'Cruz D
Autoimmun Rev; 2016 Jan; 15(1):93-101. PubMed ID: 26427983
[TBL] [Abstract][Full Text] [Related]
36. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome.
Yap DY; Yu X; Chen XM; Lu F; Chen N; Li XW; Tang CS; Chan TM
Nephrology (Carlton); 2012 May; 17(4):352-7. PubMed ID: 22295934
[TBL] [Abstract][Full Text] [Related]
37. Effect of a multitarget therapy with prednisolone, mycophenolate mofetil, and tacrolimus in a patient with type B insulin resistance syndrome complicated by lupus nephritis.
Temmoku J; Asano T; Saito K; Matsumoto H; Fujita Y; Furuya-Yashiro M; Matsuoka N; Oda A; Tanabe H; Sato S; Shio-Yano K; Sasajima T; Kiko Y; Kobayashi H; Watanabe H; Shimabukuro M; Migita K
Mod Rheumatol Case Rep; 2022 Jan; 6(1):41-46. PubMed ID: 34651654
[TBL] [Abstract][Full Text] [Related]
38. Mizoribine treatment of young patients with severe lupus nephritis: a clinicopathologic study by the tohoku pediatric study group.
Tanaka H; Oki E; Tsuruga K; Sato N; Matsukura H; Matsunaga A; Kondo Y; Suzuki J
Nephron Clin Pract; 2008; 110(2):c73-9. PubMed ID: 18758186
[TBL] [Abstract][Full Text] [Related]
39. Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children.
Fujinaga S; Kaneko K; Ohtomo Y; Murakami H; Takada M; Akashi S; Hira M; Yamashiro Y
Pediatr Nephrol; 2005 Oct; 20(10):1500-3. PubMed ID: 16021476
[TBL] [Abstract][Full Text] [Related]
40. Mizoribine versus mycophenolate mofetil in combination therapy with tacrolimus for de novo kidney transplantation: evaluation of efficacy and safety.
Ju MK; Huh KH; Park KT; Kim SJ; Cho BH; Kim CD; So BJ; Kang CM; Lee S; Joo DJ; Kim YS
Transplant Proc; 2013 May; 45(4):1481-6. PubMed ID: 23726602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
